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Stabilizing the open conformation of the integrin
headpiece with a glycan wedge increases
affinity for ligand
Bing-Hao Luo*†, Timothy A. Springer*†, and Junichi Takagi*‡§
*Center for Blood Research and Departments of †Pathology and ‡Pediatrics, Harvard Medical School, Boston, MA 02115
Contributed by Timothy A. Springer, December 31, 2002
The affinity of the extracellular domain of integrins for ligand is
regulated by conformational changes signaled from the cytoplasm.
Alternative types of conformational movement in the ligand-
binding headpiece have been proposed. In one study, electron
micrograph image averages of the headpiece of integrin aV3
show two different conformations. The open conformation of the
headpiece is present when a ligand mimetic peptide is bound and
differs from the closed conformation in the presence of an obtuse
angle between the 3 subunit hybrid and I-like domains. We tested
the hypothesis that opening of the hybrid-I-like domain interface
increases ligand-binding affinity by mutationally introducing an
N-glycosylation site into it. Both 3 and 1 integrin glycan wedge
mutants exhibit constitutively high affinity for physiological li-
gands. The data uniquely support one model of integrin activation
and suggest that movement at the interface with the hybrid
domain pulls down the C-terminal helix of the I-like domain and
activates its metal ion-dependent adhesion site, analogously to
activation of the integrin I domain.
Integrins are a family of 25 cell adhesion molecules thatmediate cell–cell, cell–extracellular matrix, and cell–pathogen
interactions and govern migration and anchorage of almost all
kinds of cells. Integrins are noncovalently associated  subunit
heterodimers. Each subunit contains a large N-terminal extra-
cellular domain, a transmembrane segment, and a cytoplasmic
C-terminal tail. One unique aspect of integrin function is that the
affinity for biological ligand can be up-regulated by a process
termed inside-out signaling (1). This is particularly important
during activation of leukocytes and platelets, where integrins are
converted to high-affinity receptors in 1 s. It has been sug-
gested that this rapid affinity up-regulation is accomplished by
a conformational change in integrin extracellular domains trig-
gered by cytoplasmic signaling pathways after cellular activation.
Several alternative models for conformational change have
been proposed. Crystal structures obtained of the extracellular
domain of V3 in Ca2 (2) or by subsequent soaking in Mn2
and a cyclic Arg-Gly-Asp (RGD) peptide (3) revealed an
unexpected bent conformation, in which the headpiece is folded
over and makes extensive contacts with the tailpiece (Fig. 1A).
Upon ligand binding, no change was seen at the interface
between the I-like and hybrid domains, and only a slight rotation
between the -propeller and I-like domains and small move-
ments within the I-like domain were seen. It was hypothesized
that both the liganded and unliganded bent structures were in the
active state (2, 3). In contrast, NMR, negative stain electron
microscopy (EM) with image averaging, ligand binding, physi-
cochemical, and mutational studies show that the bent confor-
mation is physiologic and has low ligand-binding affinity and that
activation results in a switchblade-like opening to an extended
conformation (4, 5). Two extended conformers were seen that
differed in whether there was an acute or obtuse angle between
the I-like and hybrid domains, i.e., the closed (Fig. 1B) and open
(Fig. 1C) conformations of the headpiece, respectively (5). The
closed conformation of the headpiece resembles that seen in
the V3 crystal structure. Only the open conformation of
the headpiece was seen when ligand was bound, suggesting that
in the absence of crystal lattice contacts, ligand binding induced
(i) a swing-out of the hybrid domain, and (ii) disruption of the
headpiece–tailpiece interface in which the hybrid domain is
prominent, leading to integrin extension (5). Lower resolution
rotary shadowing EM studies from another group led to a
completely different conclusion, that binding of cyclic RGD
peptide results in separation of the  and  subunits in the
headpiece and that separation between the -subunit -
propeller domain and the -subunit I-like domain induces the
high-affinity state (6, 7). Based on the negative stain EM studies,
we hypothesized that the opening of the angle between the I-like
domain and the hybrid domain in  subunit is the key feature of
the high-affinity conformer. To mimic this conformation, we
have introduced a glycan wedge at the domain interface and have
successfully engineered IIb3, V3, and 51 integrins that
show constitutively high affinity. Furthermore, the results sug-
gest that axial movement of the C-terminal helix of the  subunit
I-like domain is responsible for affinity modulation, suggesting
the existence of a common theme for activation of all integrins.
Materials and Methods
Plasmid Construction, Expression, and Ligand-Binding Activity of
Integrins on Chinese Hamster Ovary (CHO)-K1 Cells. Plasmids coding
for full-length human IIb, 3, and 1 were subcloned into
pcDNA3.1Myc-His() or pEF1V5-HisA, as described previ-
ously (5), and were introduced into the CHO-K1 cells by using
calcium phosphate precipitation. After selecting the transfected
cells in a medium containing 5 mgml geneticin G418 for 1 week,
the surviving cells were assessed for integrin expression by flow
cytometry using antibody AP3 to human 3 (American Type
Culture Collection) or antibody TS216 to human 1 (8). The
cells were then selected by fluorescence-activated cell sorting for
expression of the desired level of IIb3 or 51 integrins.
Binding of fluorescein-labeled human fibrinogen and ligand
mimetic antibody PAC-1 (gift from Sanford Shattil, The Scripps
Research Institute, La Jolla, CA) was performed as previously
described (5). For the binding of fibronectin fragment to human
1-expressing cells, the cells were incubated with 50 gml
biotinylated Fn9–10 (9) in the presence or absence of activating
mAb TS216 (10 gml) at room temperature for 30 min and
stained with FITC-streptavidin (Zymed) followed by flow cy-
tometry. Cell adhesion to human fibrinogen (Enzyme Research
Laboratories, South Bend, IN) was determined by assaying
cellular phosphatase (10).
Ligand-Induced Binding Site (LIBS) Expression. LIBS antibody AP5
was from the Fifth International Leukocyte Workshop (11), and
LIBS-1, LIBS-6, and PMI-1 antibodies were obtained from Mark
H. Ginsberg (The Scripps Research Institute). CHO-K1 cells
Abbreviations: EM, electron microscopy; LIBS, ligand-induced binding site; CHO, Chinese
hamster ovary.
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stably expressing wild-type or mutant IIb3 were incubated
with LIBS antibodies (10 gml) at room temperature for 30
min, followed by staining with FITC-conjugated secondary
antibody and flow cytometry.
Transient Transfection of 293T Cells. 293T cells were transiently
transfected with wild-type or mutant integrin cDNAs by using
calcium phosphate precipitation and were metabolically labeled
with [35S]cysteinemethionine as described (5). Labeled cell
lysates were first immunoprecipitated with AP3 antibody, eluted
with 0.5% SDS, and after the addition of 1% Nonidet P-40, were
treated with or without 500 units of PNGase F (New England
Biochemicals) at 37°C for 1 h. Material was subjected to non-
reducing SDS7% PAGE and fluorography.
Results
Design of Constitutively Active Mutant Integrin. To test the hypoth-
esis that opening the interface between the hybrid and I-like
domains regulates integrin affinity for ligand, we mutationally
introduced an N-glycosylation site in the 5–5 loop on the
bottom of the I-like domain, where the angle with respect to
the hybrid domain is most acute (Fig. 1 A). This site is far from
the ligand-binding site on the upper face of the I-like domain
containing the metal ion-dependent adhesion site and thus
should only enhance ligand binding allosterically. Furthermore,
the site is distal from both the headpiece–tailpiece interface and
the -propeller-I-like domain interface (Fig. 1 A) and thus
should not directly affect either of these interfaces, which have
also been suggested to regulate ligand binding. The 3 mutation
Asn-3053Thr introduced the Asn-303–Ile-304–Thr-305 N-
glycosylation sequon and is predicted to result in attachment of
a bulky N-glycan wedge at Asn-303.
The N-Glycan Wedge Mutant Has High Affinity for Ligand. Wild-type
or mutant 3 (3N305T) was cotransfected with wild-type IIb
subunit into CHO-K1 cells. Stable clones expressing similar
levels of mutant and wild-type IIb3 were selected. Similar
binding to wild-type and mutant receptors by mAbs to multiple
IIb and 3 epitopes including AP3 (anti-3), 7E3 (anti-3),
HA5 (anti-IIb), and AP2 (anti-IIb3 complex specific) (Fig.
2A) suggested that the mutant receptor adopts a native fold.
Soluble ligand binding was measured by using two-color flow
cytometry (5). Wild-type IIb3 on CHO-K1 cells bound soluble
fibrinogen and the ligand mimetic antibody PAC-1 only when
stimulated by Mn2 and activating mAb PT25–2 (Fig. 2 B and C).
In contrast, IIb3N305T constitutively bound fibrinogen and
PAC-1 antibody (Fig. 2 B and C). Binding by the mutant receptor
in the presence of 5 mM Ca2 was comparable with that of
wild-type receptor maximally activated with Mn2 and activating
mAb and was not further increased by the addition of activating
reagents. In contrast to the introduction of an N-glycosylation
site, mutation of Asn-303 to Trp to introduce a bulky side chain
(12) was not activating (data not shown), consistent with ample
space for the Trp side chain in the closed interface.
Fig. 1. The hybrid domain swing-out model of integrin activation. (A) Location of Asn-303 of 3 in the context of the bent conformation of the V3
extracellular fragment. Stereo diagram of the crystal structure (2) is shown as a worm presentation. Note that the site of neoglycan introduction (Asn-303, gold
CPK model) is located at the I-like domainhybrid domain boundary and faces away from the tailpiece–headpiece interface. A mutationally introduced disulfide
bridge between residue 307 in V and 563 in 3 that locks the overall bent conformation is shown as a yellow bond. Headpiece segments are color-coded as
follows: V -propeller and thigh domains in magenta; 3 I-like domain in blue; and 3 hybrid domain in cyan. Tailpiece segments (i.e., calf-1 and calf-2 domains
of V, I-EGF3, I-EGF4, and -tail domains of 3) are shown in gray. The figure was prepared by RIBBONS (27). (B) The V3 headpiece from the crystal structure.
Each domain is color coded as in A. (C) Model of the high-affinity integrin headpiece. The hybrid domain of 3 (residues 55–107 and 352–434) was rotated 30°
away from V subunit about residue 106 and submitted to the SWISS-MODEL server for refinement (28). The GlcNAc2Man7 glycan chain (yellow) from human
CD2 structure (1GYA) (29) was modeled into the inner side of the bend to simulate the glycan attachment at Asn-303. (B and C) CPK representations prepared
with SWISSPDBVIEWER (30).




































The affinity state of IIb3N305T was further tested in cell
adhesion assays. Although high affinity is required for soluble
ligand binding, basally active, i.e., low-affinity, IIb3 can
mediate cell adhesion to high-density substrates. Wild-type
IIb3 transfectants adhered to fibrinogen-coated surfaces at
coating concentrations of 1 gml (Fig. 2D). Parent CHO-K1
cells showed no adhesion even at the highest concentration of
fibrinogen (Fig. 2D). In contrast, cells expressing IIb3N305T
adhered to fibrinogen surfaces at coating concentrations as low
as 10 ngml (Fig. 2D), demonstrating markedly augmented
adhesiveness.
The Hyperactive Phenotype Is Due to the Introduced Glycan Chain. In
293T cell transient transfectants, the wedge mutant was hyper-
active in soluble fibrinogen and PAC-1 binding assays just as in
CHO-K1 cells (data not shown). Transiently transfected 293T
cells were metabolically labeled, and IIb3 complex was im-
munoprecipitated with 3 mAb AP3. Nonreducing SDSPAGE
showed that the IIb subunits migrated similarly, whereas the
mutant 3 migrated slower than wild-type 3, with an 3-kDa
increase in molecular mass (Fig. 3A, lanes 1 and 2). Furthermore,
this difference between wild-type and mutant 3 disappeared on
deglycosylation by PNGase F (Fig. 3A, lanes 3 and 4). The
increased molecular mass of the mutant 3 is therefore due to
additional N-glycosylation, suggesting that the N305T mutation
resulted in the attachment of a glycan chain at Asn-303.
To confirm the causative role of Asn-303 glycosylation of 3
in IIb3 activation, transient transfectants were treated before
and after transfection with the N-glycosylation inhibitor tunica-
mycin. Ligand binding by wild-type IIb3 was unaffected by
tunicamycin, as treated and untreated cells showed similar
fibrinogen binding after stimulation with Mn and activating mAb
(Fig. 3B). By contrast, tunicamycin treatment abolished the
Fig. 2. Expression and ligand binding activity of glycan-wedge mutants. (A)
Immunofluorescent staining of CHO-K1 transfectants. Cells express wild-type
IIb3 (thin line) or mutant IIb3 (thick line) or are mock transfectants
(dotted line). (B and C) Soluble ligand binding. Cells were incubated with
FITC-fibrinogen (B) or PAC-1 (C) in the presence of 5 mM EDTA (white bar), 5
mM Ca2 (gray bar), 1 mM Ca21 mM Mg2 (hatched bar), or 1 mM Mn2 plus
10 gml PT25–2 mAb (black bar) at room temperature for 30 min. Binding
was determined as described in Materials and Methods and was expressed as
the mean fluorescence intensity. (D) Adhesion of wild-type IIb3 (F), mutant
IIb3 (Œ), or mock transfectants () to surfaces coated with fibrinogen at the
indicated concentrations. Data are representative of three independent ex-
periments, each in triplicate. (E) Binding of Fn9–10 fragment to cells expressing
wild-type or mutant 1 integrin. Cells were incubated with 50 gml biotin-
ylated Fn9–10 in the presence (black bar) or absence (white bar) of 10 gml
anti-1 activating mAb TS216 and probed with FITC-streptavidin. Relative
amounts of ligand binding were normalized to a 100% value for binding to
wild-type 1 cells treated with TS216, after subtraction of background
binding obtained in the presence of 5 mM EDTA, and expressed as an average
of two independent experiments.
Fig. 3. Effect of N-glycosylation. (A) Immunoprecipitation. Lysates from
35S-labeled 293T cell transfectants were immunoprecipitated with mouse
anti-human 3 AP3. Precipitated wild-type (Wt) or mutant (Mut) material was
treated with () or without () PNGase F for 1 h and subjected to nonreducing
SDS7.5% PAGE and fluorography. Positions of molecular size markers are
shown on the left. (B) Effect of tunicamycin treatment on fibrinogen binding.
Transiently transfected 293T cells were treated with (Tun) or without (con-
trol) 1.5 gml tunicamycin for 24 h before transfection and 48 h after
transfection. FITC-fibrinogen binding was determined in the absence (white
bar) or presence (black bar) of activating reagents. Binding was expressed as
the percentage of mean fluorescence intensity relative to that of immuno-
fluorescent staining with AP3 mAb to 3.

















































constitutive ligand-binding activity by IIb3N305T, whereas like
wild type it was still activatable by Mn and mAb (Fig. 3B).
Therefore, carbohydrate attachment at residue 3–Asn-303 en-
dowed the receptor with high affinity rather than the mutation
of Asn-305 to Thr.
Activation of 51 with a Glycan Wedge. To generalize these
findings, similar mutations were designed in the integrin 1
subunit. The equivalent mutation in the 5–5 loop, 1-Q312T,
was not expressed well on the cell surface. Therefore, an
N-linked site was introduced nearby in the 6–6 loop with the
1-P333N mutation, which introduced the sequon Asn-333–Lys-
334–Ser-335. This mutation was well expressed in stable
CHO-K1 transfectants, in which human 1 associates with
endogenous hamster 5 to make functional 51 (13). Wild-type
human 1 transfectants bound a biotinylated fibronectin frag-
ment containing domains 9 and 10 (Fn9–10) only when the
integrin was activated with mAb TS216 to human 1 (Fig. 2E).
By contrast, 1P333N transfectants bound Fn9–10 in the absence of
mAb TS216 activation (Fig. 2E). Binding was mediated by
transfected mutant human 1, as it was inhibited by anti-human
1 blocking mAb 13 (data not shown). Thus, a glycan wedge in
the cleft between the I-like and hybrid domains can activate both
1 and 3 integrins.
The Glycan Wedge Favors the Extended Conformation of IIb3.
Activation andor ligand binding change the conformation of
IIb3, resulting in the exposure of neo-epitopes called LIBS.
Such epitopes are buried in the bent conformation in headpiece–
tailpiece and  tail– tail interfaces and are exposed in the
extended conformation (4). To probe the conformational state
of the mutant IIb3, binding of a panel of LIBS antibodies was
determined. The mAbs AP5 (anti-3, residues 1–6), LIBS1
(anti-3), LIBS6 (anti-3, residues 602–690), and PMI-1 (anti-
IIb, residues 844–859) bound poorly to the cells stably express-
ing the wild-type IIb3 in Ca2 but bound maximally when
incubated with Mn2 and RGD peptide (14–16) (Fig. 4A Upper).
In contrast, all LIBS mAbs stained cells expressing the glycan
wedge mutant IIb3 brightly even in Ca2 in the absence of
ligand, and no further increase was observed upon addition of
Mn2 and RGD peptide (Fig. 4A Lower). Another LIBS mAb
D3 (anti-3, residues 422–490) also bound constitutively to the
mutant IIb3 (data not shown).
Wedged Integrin Locked in a Bent Conformation Shows High Affinity.
The hybrid domain is located in the headpiece and has a larger
contribution than any other domain to the headpiece–tailpiece
interface (5). The glycan wedge is predicted not to push the
hybrid domain toward the tailpiece, but laterally out of the
headpiece–tailpiece interface, and thus to indirectly destabilize
it. Ligand-induced swing-out of the hybrid domain has been
previously predicted to destabilize the bent conformation by the
same mechanism, and the maximal exposure of LIBS epitopes in
the wedge mutant accords with this model of integrin activation
(5). The above studies did not define whether high ligand-
binding affinity was a proximate effect of straightening the bend
Fig. 4. Effect of glycan wedge on global unbending of 3 integrins. (A) Exposure of LIBS epitopes. Wild-type (Upper) or mutant (Lower) IIb3 CHO cell
transfectants were incubated with LIBS mAbs for 30 min at room temperature. Histograms represent binding in the presence of 5 mM Ca2 (thick line) or 1 mM
Mn2 plus 100 M GRGDSP peptide (thin line). Binding of control antibody is also shown (dotted histogram). (B) Wedge mutant of V3 can be locked in a bent
conformation. 293T cells were transiently transfected with wild-type or mutant V3, metabolically labeled, and immunoprecipitated with AP3. Disulfide bond
formation between Cys-307 of V and Cys-563 of 3N305T is shown as a high-molecular-weight band in bentwedge mutant (lane 2) after immunoprecipitation
and nonreducing SDSPAGE. Lane 1 shows wild-type V3 as a control. (C) Activation of locked-bent V3 by glycan-wedge mutation. Binding of biotinylated
Fn9–10 to 293T cells transiently expressing various V3 mutants in the presence (black bar) or absence (white bar) of activating mAb AP5 was determined. WT,
wild type V and 3; wedge, wild-type V and 3N305T; bent, VG307C and 3S563C; bentwedge, VG307C and 3S563C/N305T. Fn9–10 binding is expressed as the
percentage of mean fluorescence intensity relative to immunofluorescent staining with mAb AP3.




































between the I-like and hybrid domains or secondary to transition
from the bent to extended integrin conformation. The V3
integrin can be locked in the bent conformation by introduction
of an intersubunit disulfide bond between the  subunit -
propeller domain and  subunit I-EGF4 domain (Fig. 1 A). The
disulfide-locked integrin is inactive and resistant to activation by
Mn2 and antibodies unless a disulfide-reducing agent is added
(5). The postulated lateral swing-out of the hybrid domain would
not be blocked by this disulfide bond (Fig. 1 A). Therefore, the
two types of mutations were introduced into the same V3
integrin molecules. Immunoprecipitation and nonreducing
SDSPAGE confirmed complete formation of the disulfide
bond between the V head and 3 tail, suggesting that the
doubly mutant receptor was locked in the overall bent confor-
mation (Fig. 4B, lane 2). This notion was further confirmed by
the lack of binding by LIBS mAbs AP5, LIBS-1, LIBS-6, and D3
to VG307C3N305T/S563C, either in the presence or absence of
RGD peptide (data not shown). Because we wanted to focus on
conformational change within the ligand-binding site rather than
on its accessibility, we used a small protein ligand, Fn9–10, to
minimize any influence of unbending on accessibility. The wedge
mutation (N305T) constitutively activated the locked-bent re-
ceptor (i.e., VG307C3S563C) for binding to Fn9–10, whereas
locked-bent V3 without the wedge mutation remained inca-
pable of ligand binding even after the addition of activating mAb
(Fig. 4C). This result demonstrates that activation of high-
affinity ligand binding by the wedge mutant is not secondary to
adoption of the extended conformation of the integrin. When the
larger ligand fibrinogen was used, however, the wedge-bent
double mutant receptor did not show constitutively high activity
(data not shown). This suggests that both the affinity of the
ligand-binding site as well as its accessibility are important for
binding of larger ligands.
Discussion
When liganded and unliganded receptors assume two distinct
conformational states, it is generally possible to increase ligand
affinity by stabilizing the liganded conformation because con-
formational change and ligand binding are thermodynamically
linked (12, 17). Our findings support the proposal that the
change in angle between the I-like and hybrid domains in the
transition between the open and closed headpiece conforma-
tions regulates ligand-binding affinity (5). The findings do not
support the proposal that the closed conformation of the head-
piece is already in an active state and that no major interdomain
conformational movements are associated with ligand binding
(3). Our findings emphasize the importance of the angle between
the -subunit hybrid and I-like domains rather than separation
between the -subunit -propeller and -subunit I-like domains
in integrin activation. Whereas our studies do not specifically
address head separation, other results mitigate against it. The 
and  subunits could not be distinguished from one another in
EM studies that supported head separation (6), whereas higher
resolution EM studies in which the  and  subunits could be
distinguished showed no evidence for ligand-stimulated head
separation (5), in agreement with many other EM studies
(18–21). Furthermore, binding of cyclic RGD peptides stabilizes
rather than destabilizes  and  subunit association (7, 22, 23),
and binding of the Arg moiety of RGD to the  subunit and the
Asp moiety to the  subunit across the intersubunit interface
would be destabilized by head separation.
The -subunit I-like domain has a similar fold to the I domain,
which is present in a subset of integrin  subunits and serves as
the major ligand-binding site in the integrins in which it is
present. The I and I-like domains are each connected through
both their N and C termini to the domains in which they are
inserted, the -subunit -propeller and -subunit hybrid do-
mains, respectively. In the I domain, downward, axial displace-
ment of the C-terminal -helix causes rearrangement of residues
that comprise the metal ion-dependent adhesion site, thereby
increasing ligand affinity (24). The structural similarity between
I and I-like domains suggests a similar regulatory mechanism, in
which a downward movement of the C-terminal -helix of the
I-like domain would allosterically regulate the conformation of
the metal ion-dependent adhesion site and increase affinity for
ligands. Indeed, the glycan wedge-induced widening of the angle
between the I-like and hybrid domains is predicted to be tightly
linked to downward displacement of the C-terminal -helix of
the I-like domain, based on the overall topology of the interdo-
main connections (Fig. 5). Of the four secondary structural
elements on either side of the two interdomain connections,
three are internal -sheet strands and hence are fixed in position
by hydrogen bond networks. By contrast, the hydrogen bonds in
an -helix are all local, within the secondary structure element,
and permit displacement relative to neighboring structural ele-
ments. Furthermore, the I-like domain -helix connection to the
hybrid domain -sheet is the innermost connection, and a
piston-like downward -helix movement at this connection
would result in swiveling about a fulcrum at the other connec-
tion, opening the interface to accommodate the nearby glycan
wedge (Fig. 5).
Ligand mimetic cyclic RGD peptides can bind to the low-
affinity, bent V3 receptor with the closed interdomain angle
as shown by the crystal structure (3). Because the conforma-
tional and ligand-binding equilibria are linked, and the bent
conformation is favored in the absence of cyclic RGD peptide
binding, whereas the extended, open conformation is favored
when cyclic RGD peptide is bound and crystal lattice restraints
are absent (5), it follows that the affinity of cyclic RGD peptide
is higher for the extended open than the bent conformation of
V3. Ligand mimetics such as cyclic RGD peptides can be used
at concentrations above their KD for the low-affinity state of the
receptor and therefore can be used to drive integrin conforma-
tional change according to the law of mass action. By contrast,
physiological integrin ligands are generally encountered at con-
centrations below the KD for the low-affinity state of the
receptor; therefore, a change to a higher affinity conformation
is usually required to drive ligand binding. Additionally, macro-
molecular ligands may lack access to the binding site in the bent
integrin conformation. Physiologically, it is likely that integrins
equilibrate between multiple conformational states rather than
being locked in a specific conformation. Both signals within the
cell that affect extracellular domain conformation and ligand
Fig. 5. Linkage between swing-out of the hybrid domain and pull-down of
the I-like domain C-terminal helix. Model of 3 head (I-like and hybrid do-
mains) shows that outward swing of the hybrid domain about the pivot point
(residue 106, filled circle) results in downward shift of the C-terminal helix of
I-like domain (red). Position of Asn-303 used for glycan wedge mutation is
denoted by an white circle.

















































binding will affect these equilibria. In this regard, active regu-
lation of integrins on the cell surface is best described as moving
the equilibrium point within a conformational spectrum, rather
than turning a switch on and off.
Receptor conformational change, especially rearrangements
involving interdomain movements (12, 25, 26), is now gaining
recognition as an important mechanism for controlling ligand
binding. Thus, bulky amino acid side chain (12) and glycan
wedges may have broad applications in designing mutant recep-
tors with modified affinity. The present finding advances our
knowledge of integrin activation at the molecular level. The
successful application of the glycan wedge to 3 and 1 integrins
implies that different integrins share the common principal of
affinity modulation. The rational design of mutations that
allosterically stabilize high-affinity or low-affinity conformations
of integrins demonstrates marked advances in our understanding
of the molecular basis of affinity regulation. This progress also
holds out the promise that drugs might be designed that stabilize
the low-affinity conformation of integrins, in contrast to the
current generation of ligand-mimetic integrin antagonists that
stabilize the high-affinity conformation.
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